GIA announces the release of a comprehensive global report on the Kidney Cancer Drugs markets. The global market for Renal Cell Carcinoma (RCC) Drugs is forecast to reach $3.03 billion by the year 2017, driven by the growing preference for targeted therapies in the treatment of RCC. Additionally, growth is also expected to stem from the introduction of new emerging therapies, increased use of combination therapies, and introduction of other drug classes, such as mTOR inhibitors.

San Jose, California (PRWEB) May 07, 2012

Follow us on LinkedIn - Regardless of being a smaller segment in the overall oncology market, kidney cancer emerged as a key area of research and development, and attracted significant investments from various pharmaceutical and biotechnology majors. Kidney cancer market, for several years, lacked adequate treatment options, with patients being mainly treated with traditional therapies, such as Immunotherapy and Palliative care. Since most of the kidney cancer cases are diagnosed at a stage where they cannot be treated through surgical techniques, targeted therapies are finding increased use for the treatment of kidney cancer. Further, given the fact that kidney cancer is resistant to traditional treatment modalities, such as chemotherapy and radiation therapy, there exists significant potential for targeted therapies, in the years to come.

Among the various types of kidney cancers, Renal Cell Carcinoma (RCC) is the predominant type of kidney cancer, representing nearly 80% of the population affected from kidney cancer. Of all the targeted therapeutic options available for advanced RCC, Pfizer's Sutent has transpired to show significant potential for the treatment of the disease, and demonstrated superior efficacy compared to the traditional standard treatment of Interleukin-2 and Interferon-alpha. However, going forwards, it is estimated that GlaxoSmithKline's Votrient could threaten the dominance of Pfizer's Sutent, the long-established leader in the global RCC drugs market. Also, despite the fact that Multikinase Inhibitors dominate the RCC drugs market, growth in the future is expected to mainly emanate from other drug classes, specifically mTOR inhibitors.

With the global incidence of kidney cancer on the rise, the United States and Europe leads the global market for RCC drugs, as stated by the new market research report on Kidney Cancer Drugs. Historically, the incidence and prevalence of kidney cancer in the US has been lower in comparison to the other parts of the world. However, the incidence has been increasing constantly over the recent years, due to a rise in the number of incidentally diagnosed cases of kidney cancer. Accounting for a major share of the market, the US constitutes the world's largest market for RCC drugs. Growth is expected to mainly emanate from the Asia-Pacific market, which is forecast to register a CAGR of more than 14% during the analysis period. In terms of therapeutic classes, Multikinase Inhibitors dominate the RCC drugs market globally.

Major players profiled in the report include AVEO Pharmaceuticals, Bayer, Bristol-Myers Squibb Co, Onyx Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Merck-Serono, Novartis AG, Pfizer Inc., WILEX AG, among others.

The research report titled "Kidney Cancer Drugs: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of the kidney cancer drugs market, including the Renal Cell Carcinoma (RCC) market; the disease overview, symptoms, causes, and diagnosis; an overview of the presently available therapeutic classes, including multi-kinase inhibitors, mTOR, and others; the recent product approvals, the pipeline drugs, the key corporate initiatives, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for kidney cancer drugs market for the years 2008 through 2017 for the following geographic markets - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Key therapeutic classes analyzed include Multikinase Inhibitors, and Other Therapeutics Classes (which include Immunomodulators; mTOR Inhibitors; and Other Emerging Drug Classes).

For more details about this comprehensive market research report, please visit -
www.strategyr.com/Kidney_Cancer_Drugs_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: www.StrategyR.com/

###

For the original version on PRWeb visit: www.prweb.com/releases/prwebkidney_cancer_drugs/renal_cell_carcinoma_drug/prweb9480916.htm

...